liver disease

Pencil filling out Scantron test form
Biotech

AIRNA preps for clinical test with $155M series B

AIRNA's tech makes targeted adenosine-to-inosine edits in RNA, which the firm hopes can provide a functional cure for alpha-1 antitrypsin deficiency.
Darren Incorvaia Apr 1, 2025 7:00am
arrow back backwards u-turn turn around reverse

Ascletis slashes funds for former core programs in obesity pivot

Mar 26, 2025 10:00am
Ship sailing through stormy seas

Arbor sails into rocky gene editing waters with $74M

Mar 18, 2025 6:30am
u turn turnaround return

Vertex axes Verve gene editing pact amid shift in R&D priorities

Feb 27, 2025 9:05am
gold arrow pointing upward forward

Akero's stock doubles as midphase MASH trial hits the mark

Jan 27, 2025 8:31am
stock market down market bear market benny

Galectin's stock halves after phase 3 MASH trial misses goal

Dec 20, 2024 2:40pm